David McCrary, MD
Infectious Disease · Chesterfield, MONPI 1821034745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,503 and has fallen 61.1% since, to $585 in 2025.
Across 189 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$483
- Merck$385
- Novo Nordisk$265
- Astellas Pharma US Inc$250
- Aimmune Therapeutics, Inc.$226
- Tetraphase Pharmaceuticals, Inc.$185
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,99895%
- Education$1545%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 35 | $483 |
| Merck | 26 | $385 |
| Novo Nordisk | 19 | $265 |
| Astellas Pharma US Inc | 8 | $250 |
| Aimmune Therapeutics, Inc. | 9 | $226 |
| Tetraphase Pharmaceuticals, Inc. | 9 | $185 |
| Amgen | 9 | $149 |
| Pfizer | 9 | $147 |
| Abbott | 8 | $143 |
| AstraZeneca | 7 | $99 |
| Insmed, Inc. | 4 | $81 |
| AbbVie(2 entities) | 5 | $69 |
| Nestle Healthcare Nutrition Inc. | 3 | $67 |
| Cumberland Pharmaceuticals, Inc. | 5 | $62 |
| Lilly USA, LLC | 3 | $56 |
| Dexcom, Inc. | 2 | $48 |
| Amarin Pharma, Inc. | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Melinta Therapeutics, LLC | 2 | $29 |
| GSK | 2 | $29 |
| Neotract Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Viiv Healthcare Company | 1 | $16 |
| Novartis | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Shionogi Inc | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$3,152 in reported general payments places this provider in the 75th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $44,556 |
| FarxigaDapagliflozin Propanediol | 28 | $26,514 |
| EliquisApixaban | 18 | $22,966 |
| JardianceEmpagliflozin | 14 | $19,824 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $13,391 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $11,441 |
| ErtapenemErtapenem Sodium | 22 | $10,598 |
| Daptomycin | 12 | $10,338 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,240 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $9,913 |
| Cefepime Hcl | 32 | $4,778 |
| Vancomycin Hcl | 24 | $3,332 |
| Fosfomycin Tromethamine | 18 | $2,445 |
| SynthroidLevothyroxine Sodium | 23 | $2,324 |
| Doxycycline Hyclate | 62 | $1,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $265 | $44,55638 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $29 | $35,07249 claims |
| AstraZenecaFarxiga | $99 | $26,51428 claims |
| PfizerEliquis | $147 | $22,96618 claims |
| Boehringer IngelheimJardiance | $20 | $19,82414 claims |
| AbbVieSynthroid | $69 | $2,32423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 infectious disease providers in Missouri.
Other infectious disease in Chesterfield
- Nirmol PhilipChesterfield$31K
- Matthew GermanChesterfield$16K
- John CampbellChesterfield$11K
- Joseph FritzChesterfield$4K
- Leon RobisonChesterfield$1K
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Andrej SpecSaint Louis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.